Elan (ELN) looks to add to recent gains on rumors of a possible takeover bid from Johnson...


Elan (ELN) looks to add to recent gains on rumors of a possible takeover bid from Johnson & Johnson (JNJ), as the stock hit 52-week highs yesterday despite a bearish safety update on its Tysabri treatment for multiple sclerosis. JNJ already holds an 18% stake in ELN and pays out 49.9% of its income on its Alzheimer's drug to ELN.
Comments (1)
  • User 509088
    , contributor
    Comments (1535) | Send Message
     
    it's been a long time between splits for jnj
    30 Dec 2011, 09:18 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs